ONLINE MANUSCRIPT SUBMISSION:
An online submission and tracking service via internet facilitates a speedy and cost-effective submission
of manuscripts. The full manuscript should be submitted online via Bentham's Content
Management System (CMS) at bsp-cms.eurekaselect.com / View
Submission Instructions
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by
anyone on their behalf. The principal/corresponding author will be required to submit a Copyright Letter
along with the manuscript, on behalf of all the co-authors (if any) to confirm that the manuscript (or
any part of it) has not been published previously or is not under consideration for publication
elsewhere. Furthermore, any illustration, structure or table that has been published elsewhere must be
reported, and copyright permission for reproduction must be obtained. The figures from patent documents
are freely available on the databases and may not require any permission unless stated otherwise.
For all online submissions, please provide soft copies of all the materials (main text in MS Word or
Tex/LaTeX), figures/illustrations in TIFF, PDF or JPEG, and chemical structures drawn in ChemDraw
(CDX)/ISISDraw (TGF) as separate files, while a PDF version of the entire manuscript must also be
included, embedded with all the figures/illustrations/tables/chemical structures etc. It is advisable
that the document files related to a manuscript submission should always have the name of the
corresponding author as part of the file name, i.e., “Cilli MS text.doc”, “Cilli MS Figure 1”
etc.
It is imperative that before submission, the author(s) should carefully proofread the files for special
characters, mathematical symbols, Greek letters, equations, tables, references and images to ensure that
they appear in proper format.
References, figures, tables, chemical structures, etc. should be referred to in the text at the
appropriate places where they have been first discussed. Figure legends/captions should also be
provided.
A successful electronic submission of the manuscript will be confirmed by a system-generated email
acknowledgement to the principal/corresponding author immediately. Any queries therein should be
addressed at [email protected].
Editorial Policies:
The editorial policies of
Bentham Science Publishers
on publication ethics, peer-review, plagiarism, copyrights/licenses, errata/corrections and
article retraction/ withdrawal can be viewed at Editorial
Policy
MANUSCRIPTS PUBLISHED:
The journal publishes peer-reviewed mini- and full-length review and research articles, and drug clinical
trial studies written in English. Single Topic/Thematic Issues by invited Guest Editors are also
considered for publication.
For the submission of research articles, the author should have already filed a patent with a leading
patent authority and it should be registered, secondly the author should not have published any research
paper on the intellectual property of that patent.
As a service to authors publishing in Recent Advances in Cardiovascular Drug Discovery, all
articles will be published as open access via the journal's website until the end of 2015.
Single Topic Issues:
These special issues are peer-reviewed and may contain invited or uninvited review/mini-review
articles or a mixture of research articles and reviews/mini-reviews. A Single Topic Issue Editor
will offer a short perspective and co-ordinate the solicitation of manuscripts between 3-5 (for a
mini-Thematic Issues) to 6-10 (for full-length Thematic Issues) from leading scientists. Authors
interested in editing a single topic issue in an emerging topic of cardiovascular drug discovery may
submit their proposal at [email protected] or [email protected] for consideration.
Conference Proceedings:
For proposals to publish conference proceedings in this journal, please contact us at email: [email protected]
MANUSCRIPT LENGTH:
Mini-Reviews:
Mini-reviews should be 3000-6000 words excluding figures, structures, photographs, schemes, tables
etc.
Full-Length Reviews:
Full-length reviews should be 8000-40000 words excluding figures, structures, photographs, schemes,
tables etc.
Research Articles:
Research articles should be 4000-8000 words excluding figures, structures, photographs, schemes,
tables etc. There is a quota of 20% of published Research articles per issue in this journal.
Randomized Drug Clinical Trial Studies:
Trial studies should be 4000 to 6000 to 3000 words excluding figures, structures, photographs, schemes,
tables etc.
There is no restriction on the number of figures, tables or additional files e.g. video clips,
animation and datasets, that can be included with each article online. Authors should include all
relevant supporting data with each article (Refer to Supplementary Material section).
MANUSCRIPT PREPARATION:
The manuscript should be written in English in a clear, direct and active style. All pages must be
numbered sequentially, facilitating in the reviewing and editing of the manuscript. For further
convenience, our contracted service provider Eureka
Science can provide assistance to authors for the preparation of manuscripts.
MANUSCRIPT SECTIONS FOR PAPERS:
Manuscripts for review articles submitted to the journal may be divided into the following sections:
Copyright Letter:
Authors who publish in Bentham Science print & online journals will transfer copyright to their work to Bentham Science Publishers. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication. Once submitted to the journal, the author will not withdraw their manuscript at any stage prior to publication.
It is mandatory that a signed copyright letter also be submitted along with the manuscript by the author to whom correspondence is to be addressed. The article should not contain any such material or information that may be unlawful, defamatory, fabricated, plagiarized, or which would, if published, in any way whatsoever, violate the terms and conditions as laid down in the copyright agreement. Copyright letter can be downloaded from the journal's Web site. Download the Copyright letter.
Title:
The title of the article should be precise and brief and must not be more than 120 characters.
Authors should avoid the use of non-standard abbreviations. The title must be written in title case
except for articles, conjunctions and prepositions. Title, running title, byline, correspondent
footnote and keywords should be written as presented in original manuscript.
Short Running Title:
Authors must provide a short ‘running title’ of their manuscript.
Authors’ Names and Affiliations:
The names of the authors should be provided according to the previous citations or as the authors
would want them to be published along with the institutional affiliations, current address,
telephone, cell & fax numbers and the email address. Email address must be provided with an
asterisk in front of the name of the principal author. The corresponding author should also be
designated and the full address, telephone, cell & fax numbers and the email address must be
stated to receive correspondence and galley proofs.
Structured Abstract:
The abstract of an article should be its clear, concise and accurate summary, having no more than 250
words, and including the explicit sub-headings (as in-line or run-in headings in bold). Use of
abbreviations should be avoided and the references should not be cited in the abstract. Ideally,
each abstract should include the following sub-headings, but these may vary according to
requirements of the article.
Background
Objective
Method
Results
Conclusion
Graphical Abstract:
A Graphical Abstract is a single, concise, pictorial and visual summary of the main findings of the
article. This could either be the concluding figure from the article or a figure that is specially
designed for the purpose, which captures the content of the article for readers at a single glance.
Please find enclosed the example.
The Graphical Abstract will be displayed in online search result lists, the online contents list and
the online article, but will not appear in the article PDF file.
Please find below the important points:
Authors must supply a graphical abstract when the paper is first submitted. The graphical
abstract should summarize the contents of the paper in a concise, pictorial form useful
for rapid scanning of the journal.
The Graphical Abstract should include one or two sentences from which a reader can
understand the contents of the main discovery reported in the paper. The structure /
formulae may be included. For further details please visit: eurekaselect.com/119209
The manuscript title, authors and affiliations should be identical to those in the main
paper. An example can be found in the journal following these instructions. Graphical
abstracts must fit within the area shown in the example.
Keywords:
6 to 8 keywords must be provided.
Text Organization:
The main text should begin on a separate page and should be divided into title page, abstract and the
main text. The text may be subdivided further according to the areas to be discussed, which should
be followed by the Acknowledgement and Reference sections. The Review Article should mention any
previous important, recent and old reviews in the field and contain a comprehensive discussion
starting with the general background of the field. It should then go on to discuss the salient
features of recent developments along with relevant patents. The authors should avoid presenting
material which has already been published in a previous review. The authors are advised to present
and discuss their observations in brief. The manuscript style must be uniform throughout the text
and 10pt Times New Roman fonts should be used. The full term for an abbreviation should precede its
first appearance in the text unless it is a standard unit of measurement. Italics should be used for
Binomial names of organisms (Genus and Species), for emphasis and for unfamiliar words or phrases.
Non-assimilated words from Latin or other languages should also be italicized e.g. per se,
et al., in vitro, in vivo, in situ, etc.
For Research Articles, the manuscript should begin with the title page and abstract followed by the
main text, which must be structured into separate sections as Introduction, Material and
Methods, Results, Discussion, Conclusion, Current & Future Developments, Conflict of
Interest, Acknowledgements and References. If your research article reports the results
of a controlled health care intervention such as a Drug Clinical Trial Studies/Case Report, list
your trial registry, along with the unique identifying number. The patent registration number and
patent authority of the author's intellectual property must be cited in the article.
Standard Protocol on Approvals, Registrations, Patient Consents & Animal Protection:
All clinical investigations must be conducted according to the Declaration
of Helsinki principles. For all manuscripts reporting data from studies involving human
participants, formal review and approval by an appropriate institutional review board or ethics
committee is required. For research involving animals, the authors should indicate whether the
procedures followed were in accordance with the standards set forth in the eighth edition of
Guide for the Care and Use of Laboratory Animals (grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals_prepub.pdf;
published by the National Academy of Sciences, The National Academies Press, Washington, D.C.).
A specific declaration of such approval must be made in the copyright letter and in a stand-alone
paragraph at the end of the Methods section especially in the case of human studies where
inclusion of a statement regarding obtaining the written informed consent from each subject or
subject's guardian is a must. The original should be retained by the guarantor or corresponding
author. Editors may request to provide the original forms by fax or email.
Randomized Drug Clinical Trial Studies:
Randomized drug clinical trial studies are biomedical or health-related interventional and/or
observational research studies conducted in phases in human beings who are randomly allocated to
receive or not receive a preventive, therapeutic, or diagnostic intervention that follows a
pre-defined protocol. The study is intended to determine the safety and efficacy of approaches
to disease prevention, diagnosis and treatment.
Authors of randomized controlled trials are encouraged to submit trial protocols along with their
manuscripts. All clinical trials must be registered (before recruitment of the first
participant) at an appropriate online public trial registry that must be independent of
for-profit interest (e.g.,www.clinicaltrials.gov).
If you wish the editor(s) to consider an unregistered trial, please explain briefly why the
trial has not been registered.
All randomized clinical trials should include a flow diagram
and authors should provide a completed randomized trial
checklist (see CONSORT Flow Diagram and Checklist; www.consort-statement.org)
and a trial protocol. For further details, please visit complete
guidelines at:
http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html
Studies of diagnostic accuracy must be reported according to STARD guidelines; (http://www.stard-statement.org)
Observational studies (cohort, case-control, or cross-sectional designs) must be
reported according to the STROBE statement, and should be submitted with their
protocols; (www.strobe-statement.org).
Genetic association studies must be reported according to STREGA guidelines; (www.medicine.uottawa.ca)
Systematic reviews and meta-analyses must be reported according to PRISMA guidelines; (www.prisma-statement.org)
To find the reporting guidelines see (http://www.equator-network.org)
Important points to remember while submitting clinical trials:
Each manuscript should clearly state an objective or hypothesis; the design and methods
(including the study setting and dates, patients or participants with inclusion and
exclusion criteria, or data sources, and how these were selected for the study); the
essential features of any interventions; the main outcome measures; the main results of
the study; a comment section placing the results in context with the published
literature and addressing study limitations; and the conclusions. Data included in
research reports must be original.
Trial registry name, registration identification number, and the URL for the registry
should be included at the end of the abstract and also in the space provided on the
online manuscript submission form. If your research article reports the results of a
controlled health care intervention, list the trial registry, along with the unique
identifying number (Please note that there should be no space between the letters and
numbers of your trial registration number). Studies designed for other purposes, such as
to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempted.
All reports of randomized trials should include a section entitled “Randomization and
Masking”, within the Methods section.
The manuscript must include a statement identifying the institutional and/or licensing
committee that has approved the experiments, including any relevant details.
The SI system of units and the recommended international non-proprietary name (rINN) for
drug names must be used. Kindly ensure that the dose, route, and frequency of
administration of any drug you mention are correct.
Please ensure that the clinical trials sponsored by pharmaceutical companies follow the
guidelines on good publication practice: (http://www.gpp-guidelines.org)
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned
requirements. The author will be held responsible for false statements or failure to fulfill the
above-mentioned requirements.
Current & Future Developments:
The review / research article should conclude with a short section called “Current &
Future Developments”. The author(s) will give their opinion on the current and future important
developments on the topic discussed in their article.
Symbols and Units:
Greek symbols and special characters often undergo formatting changes and get corrupted or lost
during preparation of a manuscript for publication. To ensure that all special characters used
are embedded in the text, these special characters should be inserted as a symbol but should not
be a result of any format styling (Symbol font face) otherwise they will be lost during the
conversion to PDF/XML.
Authors are encouraged to consult reporting guidelines. These guidelines provide a set of
recommendations comprising a list of items relevant to their specific research design.
Only ISO symbols, written in italic, should be used for the various parameters. All kinds of
measurements should be reported only in International System of Units (SI). SI units should
always be written in Roman and separated from the numerical value by a space (whatever the
language).
The μ in µg or µm should be in Roman. The symbol for litre is L and that for minute is min. For
temperature, please use only one of °C, °F or K in the entire manuscript. As the Angström (1#Å =
10-10 m) is not an SI unit, it should be replaced by the nanometre (1nm =
10-9 m) or by the picometer (1pm = 10-12 m): 1# Å = 0.1nm = 100 pm.
Multiple units should be written with negative superscripts (for example, 25mgμL-1µs-1). The
list of notations should appear just before the first paragraph of full text.
A list of symbols and units should be provided if used extensively throughout the text.
Conclusion:
A small paragraph summarizing the contents of the article, presenting the final outcome of the
research or proposing further study on the subject, may be given at the end of the article under the
Conclusion section.
List of Abbreviations:
If abbreviations are used in the text either they should be defined in the text where first used, or
a list of abbreviations can be provided.
Conflict of Interest:
Financial contributions and any potential conflict of interest must be clearly acknowledged under the
heading ‘Conflict of Interest’. Authors must list the source(s) of funding for the study. This
should be done for each author.
Acknowledgements:
Any research assistants or other individuals who assisted with the research but are not listed as authors, such as those who carried out the literature review, produced, computerized, and analyzed the data, or helped with the language, writing, or proofreading of the article, or offered any comments or suggestions, should be acknowledged. Briefly, everyone who has contributed significantly to the improvement of the paper should be acknowledged. It is recommended to mention the "Declared None" if there is no acknowledgement for the study.
Guest or honorary authorship based solely on position (e.g. research supervisor, departmental head)
is discouraged.
The specific requirements for authorship have been defined by the International Committee of Medical
Journal Editors (ICMJE; www.icmje.org). Examples of authors'
contributions are: 'designed research/study', 'performed research/study', 'contributed important
reagents', 'collected data', 'analyzed data', 'wrote paper' etc. This information must be included in the submitted manuscript as a separate paragraph under the heading 'Authors' Contribution'. The
corresponding author is responsible for obtaining permission from all co-authors for the submission
of any version of the manuscript and for any changes in the authorship.
References:
References should be numbered sequentially [in square brackets] in the text and listed in the same
numerical order in the reference section. All references must be complete and accurate. Online
citations should include the date of access. Journal titles should conform to the present Index
Medicus abbreviations. It is necessary to list all authors if the total number of authors is 6 or
less, and for more than 6 authors list the first 6 authors and then use et al. The reference numbers
must be finalized and the bibliography must be fully formatted before submission.
References should be listed in the following Vancouver Style:
Journal:
Boehm M, Nabel EG. Angiotensin-converting enzyme 2 - a new cardiac regulator. N Engl J
Med 2002; 347: 1795-7.
Book:
Crabtree RH. The organometallic chemistry of the transition metals. 3rd ed.
Wiley & Sons: New York 2001.
Book Chapter:
Yeh DC, Rocco T. In: David EG, Armen HT, Ehrin JA, April WA, Eds. Integrative
cardiovascular pharmacology. Philadelphia: Lippincott Williams & Wilkins 2005:
375-83.
Conference Proceedings:
Jakeman DL, Withers SGE. Carbohydrate bioengineering: interdisciplinary approaches.
Proceedings of the 4th Carbohydrate Bioengineering Meeting. Stockholm, Sweden, June
10-13, 2001.
Meeting Abstract:
Hoffman BJ. Metabolism: Amino acid transporters as targets for therapeutic intervention.
American Chemical Society - 228th National Meeting. Philadelphia, USA (2004).
Website:
National Library of Medicine. Specialized Information Services: Toxicology and
Environmental Health. Available at: http://sis.nlm.nih.gov/Tox/ToxMain.html
(Accessed on: May 23, 2009).
Thesis:
Mackel H. Capturing the spectra of silicon solar cells. PhD Thesis, The Australian
National University, Canberra, Australia, December 2004.
Patent:
As a service, the Publishers can provide each author a certain number of relevant patents
to assist them in writing their article. All patent application references will be
provided by the author and will be published as it is.
Patent Reference Style:
All inventors’ names of the cited patents must be stated with the title, publication
number and the year of publication e.g. Chesnut, J.D., Carrino, J.,
Leong, L., Madden, K., Gleeson, M.A.G., Fan, J., Brasch, M.A., Cheo, D., Hartley,
J.L., Byrd, D.R.N., Temple, G.F.
Methods and compositions for synthesis of nucleic acid molecules using multiple
recognition sites. US7198924 (2007).
Citation of the patents will be according to the international convention as follows:
WO Patents: 1978-2003:
Yue, S., Johnson, I., Haugland, R. Dimers of unsymmetrical cyanine dyes.
WO9306482 (1993).
Li, Q., Guo, Z.Y., Kane, T., Liu, Z. System and method for temperature gradient
capillary electrophoresis. WO03033743 (2003).
WO Patents: 2004 onwards:
Abad, A., Dong, H., Lo, S.B., McCutchen, B.F., Shi, X. Method for identifying
novel genes. WO2008011565 (2008).
US Patent Applications: 2001 onwards:
2001 onwards Adang, A.E.P., Van Boeckel, C.A.A., Peters, J.A.M., Grootenhuis,
P.D.J. Thrombin inhibitors. US20010007764 (2001).
Stefanadis, C., Kipshidze, N. Method and devices for treatment of vulnerable
(unstable) and/or stable atherosclerotic plaque by disrupting pathologic vasa
vasorum of the atherosclerotic plaque. US20090030494 (2009).
Issued/Granted US Patents:
Hultmark, D., Steiner, H., Rasmuson, T., Boman, H.G. Bacteriolytic proteins.
US4355104 (1982).
Garbe, C., Schittek, B. Antimicrobially active peptide. US7348409 (2008
).
EP Patents:
Sutherland, J.W., Patterson, D.R. Homogeneous method for assay of double-stranded
nucleic acids using fluorescent dyes and kit useful therein. EP684316 (
1995).
Une, K., Saito, J., Hayashi, T. Method for assaying Reg IV mRNA. EP1780289 (
2007).
Some important points to remember:
Superscripts in the in-text citations and reference section should be avoided.
Abstracts, unpublished data and personal communications (which can only be
included if prior permission has been obtained) should not be given in the
reference section but they may be mentioned in the text and details provided as
footnotes.
The authors are encouraged to use a recent version of EndNote (version 5 and
above) or Reference Manager (version 10) when formatting their reference list,
as this allows references to be automatically extracted.
Tables:
Data tables should be submitted in Microsoft Word table format.
Each table should include a title/caption being explanatory in itself with respect to the
details discussed in the table. Detailed legends may then follow.
Table number in bold font i.e. Table 1, should follow a title. The title should
be in small case with the first letter in caps. A full stop should be placed at the end of
the title.
Tables should be embedded in the text exactly according to their appropriate placement in the
submitted manuscript.
Columns and rows of data should be made visibly distinct by ensuring that the borders of each
cell are displayed as black lines.
Tables should be numbered in Arabic numerals sequentially in order of their citation in the
body of the text.
If a reference is cited in both the table and text, please insert a lettered footnote in the
table to refer to the numbered reference in the text.
Tabular data provided as additional files can be submitted as an MS Excel spreadsheet.
Figures/Illustrations:
All authors must strictly follow the guidelines below for preparing illustrations for publication in
Recent Advances in Cardiovascular Drug Discovery
. If the figures are found to be sub-standard, then the manuscripts will be rejected and the
authors offered the option of figure improvement professionally by Eureka Science. The costs for such
improvement will be charged to the authors.
Illustrations should be provided as separate files, embedded in the text file, and must be numbered
consecutively in the order of their appearance. Each figure should include only a single
illustration which should be cropped to minimize the amount of space occupied by the illustration.
If a figure is in separate parts, all parts of the figure must be provided in a single composite
illustration file.
Photographs should be provided with a scale bar if appropriate, as well as high-resolution component
files.
Scaling/Resolution:
Line Art image type is normally an image based on lines and text. It does not contain tonal or
shaded areas. The preferred file format should be TIFF or EPS, with the color mode being
Monochrome 1-bit or RGB, in a resolution of 900-1200 dpi.
Halftone image type is a continuous tone photograph containing no text. It should have the
preferred file format TIFF, with color mode being RGB or Grayscale, in a resolution of 300 dpi.
Combination image type is an image containing halftone, text or line art elements. It should have
the preferred file format TIFF, with color mode being RGB or Grayscale, in a resolution of
500-900 dpi.
Formats:
Illustrations may be submitted in the following file formats:
Illustrator
EPS (preferred format for diagrams)
PDF (also especially suitable for diagrams)
PNG (preferred format for photos or images)
Microsoft Word (version 5 and above; figures must be a single page)
PowerPoint (figures must be a single page)
TIFF
JPEG (conversion should be done using the original file)
BMP
CDX (ChemDraw)
TGF (ISISDraw)
Bentham Science does not process figures submitted in GIF format.
For TIFF or EPS figures with considerably large file size restricting the file size in online
submissions is advisable. Authors may therefore convert to JPEG format before submission as this
results in significantly reduced file size and upload time, while retaining acceptable quality.
JPEG is a ‘lossy’ format. However, in order to maintain acceptable image quality, it is
recommended that JPEG files are saved at High or Maximum quality.
Zipit or Stuffit tools should not be used to compress files prior to submission as the resulting
compression through these tools is always negligible.
Please refrain from supplying:
Graphics embedded in word processor (spreadsheet, presentation) document.
Optimized files optimized for screen use (like GIF, BMP, PICT, WPG) because of the low
resolution.
Files with too low a resolution.
Graphics that are disproportionately large for the content.
Image Conversion Tools:
There are many software packages, many of them freeware or shareware, capable of converting to
and from different graphics formats, including PNG.
General tools for image conversion include Graphic Converter on the Macintosh, Paint Shop Pro,
for Windows, and ImageMagick, available on Macintosh, Windows and UNIX platforms.
Bitmap images (e.g. screenshots) should not be converted to EPS as they result in a much larger
file size than the equivalent JPEG, TIFF, PNG or BMP, and poor quality. EPS should only be used
for images produced by vector-drawing applications such as Adobe Illustrator or CorelDraw. Most
vector-drawing applications can be saved in, or exported as, EPS format. If the images were
originally prepared in an Office application, such as Word or PowerPoint, original Office files
should be directly uploaded to the site, instead of being converted to JPEG or another format of
low quality.
Color Figures/Illustrations:
The cost for each individual page of color figures/plates/illustrations is US$ 997
.
Color figures should be supplied in CMYK and not RGB colors.
Chemical Structures:
Chemical structures must be prepared in ChemDraw (CDX) and provided as separate file.
Structure Drawing Preferences:
[As according to the ACS style sheet]
|
Drawing Settings:
|
| Chain angle |
120° |
| Bond spacing |
18% of width |
| Fixed length |
14.4 pt (0.500cm, 0.2in) |
| Bold width |
2.0 pt (0.071cm, 0.0278in) |
| Line width |
0.6 pt (0.021cm, 0.0084in) |
| Margin width |
1.6 pt (0.096cm) |
| Hash spacing |
2.5 pt (0.088cm, 0.0347in) |
|
Text settings:
|
| Font |
Times New Roman |
| Size |
8 pt |
|
Under the Preference Choose:
|
| Units |
points |
| Tolerances |
3 pixels |
|
Under Page Setup Use:
|
| Paper |
US letter |
| Scale |
100% |
Supportive/Supplementary Material:
We do encourage to append supportive material, for example a PowerPoint file containing a talk about
the study, a PowerPoint file containing additional screenshots, a Word, RTF, or PDF document showing
the original instrument(s) used, a video, or the original data (SAS/SPSS files, Excel files, Access
Db files etc.) provided it is inevitable or endorsed by the journal's Editor.
Supportive / Supplementary material intended for publication must be numbered and referred to in the
manuscript but should not be a part of the submitted paper. In-text citations as well as a section
with the heading "Supportive / Supplementary Material" before the "References" section should be
provided. Here, all Supportive / Supplementary Material should be listed a brief caption line for
each file describing its contents must be included.
Any additional files will be linked into the final published article in the form supplied by the
author, but will not be displayed within the paper. They will be made available in exactly the same
form as originally provided only on our website. Please also make sure that each
additional file is a single table, figure or movie (please do not upload linked worksheets or PDF
files larger than one sheet). Supportive/Supplementary material must be provided in a single zipped
file not larger than 4 MB.
Authors must clearly indicate if these files are not for publication but meant for the
reviewers'/editors' perusal only.
PERMISSION FOR REPRODUCTION
Permission to Reuse Bentham Content
Bentham Science has collaborated with the Copyright Clearance Center to meet our customer’s licensing,
besides rights & permission needs.
The Copyright Clearance Center’s RightsLink® service makes it faster and easier to secure permission from
Bentham Science’s journal titles. Visit
Journals by Title and locate the desired
content. Then go to the article’s abstract and click on “Rights and Permissions” to open the
RightsLink’s page. If authors can't find the content they are looking for or can't get the rights they
need, please contact us at
[email protected]
Third-Party Permissions
Authors are responsible for managing the inclusion of third-party content as an author/editor of a work.
We refer to 'third party content' as any work that authors haven't developed themselves and have copied
or adapted from other sources. Text, figures, photographs, tables, screenshots, and other items may be
included.
Unless the figure is in the public domain (copyright-free) or permitted for use under Creative Commons
or other open licences, the author must get permission from the copyright holder(s).
Published/reproduced material should not be included unless written permission has been obtained from the
copyright holder, which should be forwarded to the Editorial Office in case of acceptance of the article
for publication.
Open Access Articles
Articles are licensed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) (https://creativecommons.org/licenses/by/4.0/legalcode), which permits unrestricted distribution and reproduction in any medium, as long as the work is properly credited/attributed. For more details, please visit Open Access Policy
AUTHORS AND INSTITUTIONAL AFFILIATIONS:
The Corresponding Author must provide a final list of authors at the time of submission, ensuring the correct sequence of the names of authors, which will not be considered for any addition, deletion or rearrangement after final submission of the manuscript. The email address of the principal author should be provided with an asterisk. However, the complete address, business telephone numbers, fax numbers and e-mail address of the corresponding author must be stated to receive correspondence and galley proofs. Bentham Science Publishers recommends that all contributors regularly update their profiles on SCOPUS/ORCID and other databases.
The corresponding author must have the approval of all other listed authors for the submission and publication of all versions of the manuscript.
REVIEWING AND PROMPTNESS OF PUBLICATION:
All papers submitted for publication are immediately subjected to editorial scrutiny, usually in
consultation with members of the journal Editorial Advisory Board and outside independent reviewers.
Every effort will be made to peer review submitted papers quickly. Papers which are delayed by authors
in revision for more than 30 days will have to be re-submitted as a new submission. Papers accepted for
publication are typeset and proofs are dispatched to authors for any corrections prior to final
publication.
PAGE CHARGES:
No page charges will be levied to the authors.
LANGUAGE AND EDITING:
Authors should seek professional assistance for the correction of grammatical, scientific, and typographical errors before submission of the revised version of the article for publication.
You may use the professional editing services of our nominated English Language editing organizations TopEdit or Eureka Science.
Please note that we accept a language certificate, only from one of the above two language editing organizations.
언어 및 편집:
영문 오타가 많은 원고는 출판되지 않을 것입니다. 영문 오타를 없애겠다는 조건으로 받은 원고는 영어 편집 전문회사인 유럽 공동 기술개발 기구로부터 가격 견적서가 보내 질 것입니다.
영어 작문에 어려움이 있는 비영어권 국가의 저자들은 원고를 학술지에 제출하기 전에 영어 편집회사와 접촉할 것을 권합니다. 영어 편집 견적서를 받기 위해서 교정될 원고의 단어수를
적은 메일을 유럽 공동 기술개발 기구 메일인 [email protected] 로 보내시기 바랍니다.
语言和编辑:
含有很多英文印刷错误的提交稿将不予发表。接受发表的稿件其英文写作应是正确的；专业的语言编辑公司（尤里卡科学），可对稿件的英文润色提供报价。建议非英语国家、且英文写作欠佳的作者在投稿前先与语言编辑公司联系。请与尤里卡科学联系
[email protected].
EDITION ET LANGUE:
Les manuscrits soumis avec plusieurs erreurs typographiques en Anglais ne seront pas publiés en l’état.
Les manuscrits sont acceptés pour publication à la condition que l'anglais utilisé soit corrigé après la
soumission et seront envoyés pour examen à Eureka
Science, une société d'édition de langue professionnelle. Les auteurs en provenance de pays où
la langue est différente de l'anglais et qui ont de médiocres compétences en anglais écrit, sont priés
de contacter la société d'édition de langue avant de soumettre leur manuscrit à la revue. Merci de
contacter Eureka Science à [email protected] pour un devis en indiquant le nombre
total de mot de l’article à éditer.
PROOFS:
Authors will receive page proofs of their accepted paper before publications. To avoid delays in
publication, proofs should be checked immediately for typographical errors and returned within 48
hours. Major changes are not acceptable at the proof stage.
The corresponding author will be solely responsible for ensuring that the revised version of the
manuscript incorporating all the submitted corrections receives the approval of all the co-authors of
the manuscript.
REPRINTS:
Printed reprints and e-prints may be ordered from the Publisher prior to publication of the article.
First named authors may also order a personal online subscription of the journal at 50% off the normal
subscription rate by contacting the subscription department at e-mail: [email protected].
Gold Open Access:
Bentham Science also offers authors the choice of “Open Access Plus (Gold Open Access)” publication of
articles at a fee of US$ 450 per article. This paid service allows for articles to be
disseminated to a much wider audience, on the terms of the Creative Commons CC BY-NC-ND
(Attribution-NonCommercial-NoDerivs) Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors are asked to indicate whether or not they wish to pay to have their article made more widely
available on this “Open Access Plus (Gold Open Access)” basis. Where an author does not opt-in to this
paid service, then the author’s article will be published only on Bentham Science’s standard
subscription-based access, at no additional cost to the author.
For more information please contact us at e-mail: [email protected]
COPYRIGHT:
Authors who publish in Bentham Science print & online journals will transfer
copyright to their work to
Bentham Science Publishers
. Submission of a manuscript to the respective journals implies that all authors have read and
agreed to the content of the Copyright Letter or the Terms and Conditions. It is a condition of
publication that manuscripts submitted to this journal have not been published and will not be
simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the
article for publication the authors agree that the publishers have the legal right to take appropriate
action against the authors, if plagiarism or fabricated information is discovered. By submitting a
manuscript the authors agree that the copyright of their article is transferred to the publishers if and
when the article is accepted for publication. Once submitted to the journal, the author will not
withdraw their manuscript at any stage prior to publication.
SELF-ARCHIVING
By signing the Copyright Letter the authors retain the rights of self-archiving. Following are the
important features of self-archiving policy of Bentham Science journals:
Authors can deposit the first draft of a submitted article on their personal websites, their
institution’s repositories or any non-commercial repository for personal use, internal
institutional use or for permitted scholarly posting.
Authors may deposit the ACCEPTED VERSION of the peer-reviewed article on their personal websites,
their institution’s repository or any non-commercial repository such as PMC, arXiv after
12 MONTHS of publication on the journal website. In addition, an acknowledgement must
be given to the original source of publication and a link should be inserted to the published
article on the journal's/publisher’s website.
If the research is funded by NIH, Wellcome Trust or any other Open Access Mandate, authors are
allowed the archiving of published version of manuscripts in an institutional repository after
the mandatory embargo period. Authors should first contact the Editorial Office of the journal
for information about depositing a copy of the manuscript to a repository. Consistent with the
copyright agreement, Bentham Science does not allow archiving of FINAL PUBLISHED VERSION of
manuscripts.
The link to the original source of publication should be provided by inserting the DOI number of
the article in the following sentence: “The published manuscript is available at EurekaSelect
via https://www.eurekaselect.com/openurl/content.php?genre=article&doi=.
There is no embargo on the archiving of articles published under the OPEN ACCESS PLUS (GOLD OPEN
ACCESS) category. Authors are allowed deposition of such articles on institutional,
non-commercial repositories and personal websites immediately after publication on the journal
website.
PLAGIARISM PREVENTION:
Bentham Science Publishers uses the iThenticate software to detect instances of overlapping and similar
text in submitted manuscripts. iThenticate software checks content against a database of periodicals,
the Internet, and a comprehensive article database. It generates a similarity report, highlighting the
percentage overlap between the uploaded article and the published material. Any instance of content
overlap is further scrutinized for suspected plagiarism according to the publisher’s Editorial Policies.
Bentham Science allows an overall similarity of 20% for a manuscript to be considered for publication.
The similarity percentage is further checked keeping the following important points in view:
Low Text Similarity:
The text of every submitted manuscript is checked by using the Content Tracking mode in iThenticate.
The Content Tracking mode ensures that manuscripts with an overall low percentage similarity (but
which may have a higher similarity from a single source) are not overlooked. If the similarity level
is significantly high, then the manuscript is returned to the author for paraphrasing the text and
citing the original source of the copied material.
It is important to mention that the text taken from different sources with an overall low similarity
percentage will be considered as a plagiarized content if the majority of the article is a
combination of copied material.
High Text Similarity:
There may be some manuscripts with an overall low similarity percentage, but a higher percentage from
a single source. For instance, a manuscript may have less than 20% overall similarity but there may
be 15 % similar text taken from a single article; the similarity index in such cases is higher than
the approved limit for a single source. Authors are advised to thoroughly rephrase the similar text
and properly cite the original source to avoid plagiarism and copyright violation.
Types of Plagiarism:
We all know that scholarly manuscripts are written after a thorough review of previously published
articles. It is therefore, not easy to draw a clear boundary between legitimate representation and
plagiarism. However, the following important features can assist in identifying different kinds of
plagiarized content. These are:
Reproduction of others words, sentences, ideas or findings as one’s own without proper
acknowledgement.
Text recycling, also known as self-plagiarism. It is an author’s use of a previous
publication in another paper without proper citation and acknowledgment of the original
source.
Paraphrasing poorly: Copying complete paragraphs and modifying a few words without changing
the structure of original sentences or changing the sentence structure but not the words.
Verbatim copying of text without putting quotation marks and not acknowledging the work of
the original author.
Properly citing a work but poorly paraphrasing the original text is considered as
unintentional plagiarism. Similarly, manuscripts with language somewhere between
paraphrasing and quoting are not acceptable. Authors should either paraphrase properly or
quote and in both cases, cite the original source.
Higher similarity in the abstract, introduction, materials and methods, and discussion and
conclusion sections indicates that the manuscript may contain plagiarized text. Authors can
easily explain these parts of the manuscript in many ways. However, technical terms and
sometimes standard procedures cannot be rephrased; therefore Editors must review these
sections carefully before making a decision.
Plagiarism in Published Manuscripts:
Published manuscripts which are found to contain plagiarized text are retracted from the journal
website after careful investigation and approval by the Editor-in-Chief of the journal. A
‘Retraction Note’ as well as a link to the original article is published on the electronic version
of the plagiarized manuscript and an addendum with retraction notification in the journal concerned.
For further details, please visit: https://www.eurekaselect.com/research-misconduct
E-PUB AHEAD OF SCHEDULE:
Bentham Science Publishers is pleased to offer electronic publication of accepted papers prior to scheduled publication.
These peer-reviewed papers can be cited using the date of access and the unique DOI number. Any final
changes in manuscripts will be made at the time of print publication and will be reflected in the final
electronic version of the issue. Articles ahead of schedule may be ordered by pay-per-view at the
relevant links by each article stated via the E-Pub
Ahead of Schedule
Disclaimer:
Articles appearing in E-Pub Ahead-of-Schedule sections have been peer-reviewed and accepted for
publication in this journal and posted online before scheduled publication. Articles appearing here
may contain statements, opinions, and information that have errors in facts, figures, or
interpretation. Accordingly,
Bentham Science Publishers
, the editors , authors and their respective employees are not responsible or liable for
the use of any such inaccurate or misleading data, opinion or information contained of articles in
the E-Pub Ahead-of-Schedule.
Member of Cope
